BRAIN BIOTECH AG |
Market Closed -
Other stock markets
|
After market 02:03:56 pm | |||
| 3.260 EUR | +0.62% |
|
3.150 | -3.37% |
| Jan. 14 | BRAIN Biotech AG Reports Earnings Results for the Full Year Ended September 30, 2024 | CI |
| Dec. 12 | BRAIN Biotech AG - Analyst/Investor Day |
Summary: BRAIN Biotech AG
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Highlights: BRAIN Biotech AG
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses: BRAIN Biotech AG
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings Chart: BRAIN Biotech AG
Source: Surperformance
| Composite Fundamentals | Composite Valuation | Composite Momentum | Capi. ($) | ||
|---|---|---|---|---|---|
| - | 73.7M | ||||
| - | 160M | ||||
| Average | - | 116.66M | |||
| Weighted average by Cap. | - |
Investor Rating
Trading Rating
ESG MSCI
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- BNN Stock
- Ratings BRAIN Biotech AG